Gilead Sciences (GILD) News Today

Gilead Sciences, Inc. (NASDAQ: GILD) stock moved today on a mix of analyst revisions, legal developments and insider activity.

• Positive Sentiment: Leerink Partnrs raised its Q3 2025 EPS forecast to $2.37 from $2.26, signaling stronger expected results. Q3 EPS Forecast Increased by Analyst
• Positive Sentiment: Bernstein maintained its Buy rating and $120 price target, citing upside from the new HIV therapy Yeztugo. Bernstein Maintains Buy Rating
• Neutral Sentiment: Director Jeffrey Bluestone sold 5,000 shares at an average of $109.74, reducing his stake by about 36%. Bluestone Sells 5,000 Shares
• Neutral Sentiment: Gilead struck a deal to supply its HIV vaccine to low- and middle-income nations, broadening its global footprint. HIV Vaccine Deal
• Negative Sentiment: Leerink Partnrs cut its Q2 2025 EPS estimate to $1.91 from $2.25, reflecting a softer near-term outlook. Q2 EPS Reduced by Analyst
• Negative Sentiment: The Schall Law Firm launched a securities-law investigation into Gilead, creating legal overhang. Fraud Investigation
• Negative Sentiment: Gilead agreed to pay $202 million to settle claims over its HIV drug speaker program, adding to legal expenses. 202M Settlement Over HIV Drug
• Negative Sentiment: The stock underperformed the broader market after these combined headwinds. Fell More Than Market